Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response (Q31911584)

5 July 2017

title

Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response (English)

1 reference

5 July 2017

1 reference

1 reference

Kancherla RR

1

1 reference

5 July 2017

Nair JS

2

1 reference

5 July 2017

Ahmed T

3

1 reference

5 July 2017

Durrani H

4

1 reference

5 July 2017

Seiter K

5

1 reference

5 July 2017

Mannancheril A

6

1 reference

5 July 2017

Tse-Dinh YC

7

1 reference

5 July 2017

language of work or name

English

0 references

publication date

1 February 2001

1 reference

5 July 2017

1 reference

5 July 2017

volume

91

1 reference

5 July 2017

issue

3

1 reference

5 July 2017

page(s)

463-471

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

5 July 2017

1 reference

Eukaryotic DNA topoisomerases I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Topoisomerase Poisons: Harnessing the Dark Side of Enzyme Mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Phase I Clinical and Pharmacology Study of Topotecan Given Daily for 5 Consecutive Days to Patients With Advanced Solid Tumors, With Attempt at Dose Intensification Using Recombinant Granulocyte Colony-Stimulating Factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Topoisomerase II: A specific marker for cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Effects of CPT-11 in combination with other anti-cancer agents in culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

p53 regulates the minimal promoter of the human topoisomerase IIalpha gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

p53 mutations in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Cytotoxic efficacy with combinations of topoisomerase I and topoisomerase II inhibitors in sensitive and multidrug-resistant L1210 mouse leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Experimental studies on biochemical modulation targeting topoisomerase I and II in human tumor xenografts in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

Phase I trial of sequential topotecan followed by etoposide in adults with myeloid leukemia: a National Cancer Institute of Canada Clinical Trials Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F1097-0142%2820010201%2991%3A3%3C463%3A%3AAID-CNCR1023%3E3.0.CO%3B2-R

10.1002/1097-0142(20010201)91:3<463::AID-CNCR1023>3.0.CO;2-R

21 January 2018

Identifiers

DOI

1 reference

5 July 2017

1 reference